Study at a glance
Why do different tissues handle vitamin D differently?
They differ in how vitamin D enters their cells, how much they activate and how they break it down. The same blood level does not reveal every tissue’s local activity.
Can cells take up vitamin D attached to a carrier protein?
Some can. Kidney cells have specialised ways to take it in, and similar routes have been studied in other cell types. Vitamin D attached to a protein is not automatically unavailable to tissues.
Do vitamin D enzymes follow the same rules everywhere?
No. Kidney activation responds strongly to hormones involved in mineral balance. Other cells can respond to local signals, including signals from the immune system.
What do the cell and mouse experiments establish?
They show particular ways that cells take in, activate and break down vitamin D. They do not establish a supplement dose or prove a health benefit in people.
Read the full article below ↓Vitamin D metabolism is not one identical pathway copied into every cell. The same circulating metabolite can encounter different uptake machinery, different CYP27B1 regulation and different catabolic capacity depending on tissue and cell state. Those differences are part of the physiology, not noise around it.
Substrate access differs before metabolism begins
Renal proximal tubular cells use megalin, cubilin and associated endocytic machinery to recover DBP-bound vitamin D metabolites from the filtrate. This gives the kidney a highly developed route for conserving 25(OH)D and delivering substrate to intracellular enzymes. Some extrarenal cells also use receptor-mediated uptake, but the evidence is heterogeneous rather than universal.
In tissues without an equivalent uptake system, free or bioavailable metabolite can be more important. The same circulating total 25(OH)D concentration can therefore produce different intracellular substrate availability in different cell types.
The same CYP27B1 reaction can sit inside different regulatory programmes
CYP27B1 performs 1α-hydroxylation in kidney and extrarenal tissues, but its regulation changes with context. Renal CYP27B1 is integrated with PTH, FGF23 and mineral feedback. In macrophages, keratinocytes and other local systems, cytokines and innate-immune signals can become major regulators.
That distinction separates enzyme identity from physiological function. Detecting CYP27B1 expression shows capacity for local activation; it does not prove the magnitude of that activation, the signals controlling it, or a major contribution to circulating 1,25(OH)2D.
Catabolic capacity is tissue-dependent too
CYP24A1 provides a major VDR-linked negative-feedback route in many target cells, but it is not the only route everywhere. Liver and intestine have substantial CYP3A4 activity capable of metabolising 25(OH)D and 1,25(OH)2D. Even within CYP24A1 metabolism, C24 and C23 pathways generate different products, some of which retain biological activity.
Cellular exposure therefore reflects the balance between entry, activation, receptor signalling and removal. Tissue identity changes the relative strength of each step.
Why this tissue-specific view is more useful
Two opposite simplifications fail. A purely endocrine picture misses established extrarenal CYP27B1 and local activation. A model in which every CYP27B1-positive tissue is a self-contained miniature kidney ignores major differences in uptake, chromatin, regulatory signals, catabolic enzymes and physiological scale.
The more defensible model is a shared set of molecular tools deployed under tissue-specific rules. That is why the cellular pathway has to be interpreted alongside Vitamin D Intracrine Activity, Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1), and Vitamin D Clearance and Degradation rather than treating any one of them as universal.
Specific experiments show why tissue context cannot be treated as a footnote
The uptake evidence provides a direct example. In renal experiments, blocking megalin-dependent endocytosis with receptor-associated protein reduced DBP uptake to about 8.2% of control, showing how strongly the proximal tubule can depend on receptor-mediated recovery. Differentiated muscle cells behaved differently: labelled 25(OH)D accumulation was roughly two: to three-fold higher in myotubes than in myoblasts, and RAP reduced myotube uptake by 66% over 16 hours. The mechanism is therefore both tissue: and differentiation-dependent.
The activation evidence adds a second layer. Macrophages and keratinocytes can regulate CYP27B1 through cytokine and innate-immune signals that are not equivalent to the renal PTH/FGF23 programme. This can become clinically visible in granulomatous disease, where poorly restrained macrophage production of 1,25(OH)2D can contribute to hypercalcaemia.
The degradation evidence adds a third. Cyp24a1-null mice show an approximately ten-fold extension of 1,25(OH)2D plasma half-life, from about 6 to about 60 hours, demonstrating the importance of catabolic capacity. Yet CYP3A4 offers an additional route in liver and intestine, and CYP24A1 itself can direct metabolism through chemically different C24 and C23 pathways. Tissue context therefore changes not just the rate of metabolism but also which routes are available.
These tissue-specific distinctions give practical meaning to Vitamin D Metabolism at the Cellular Level without treating one tissue programme as universal.
The pathway bridge follows how substrate access, activation, signalling and clearance connect in sequence.
Related reading
Altered molecular repertoire of immune system by renal dysfunction in the elderly: is prediction and targeted prevention in the horizon?
Here, we investigated the relationship between serum 25-hydroxyvitamin D (25(OH)D) level and T cell differentiation in chronic HD patients.
Original paper ↗Read more →Chronic Kidney Disease and Altered Vitamin D Metabolism: Full Evidence Review
How chronic kidney disease alters vitamin D activation, substrate handling, degradation, PTH, FGF23 and mineral regulation, with important physiological limits.
Read more →Chronic Kidney Disease and Altered Vitamin D Metabolism: Study Summary
concise evidence summary of how CKD can alter vitamin D activation, substrate recovery, degradation and calcium-phosphate endocrine regulation.
Read more →Bone Turnover Markers, DXA and Mineral Metabolism in Long-Term Kidney Transplant Recipients: A Cross-Sectional Comparative Study
Between-group comparisons were adjusted for age, sex, body mass index (BMI) and postmenopausal status, with sensitivity analyses restricted to participants with low bone mass.
Original paper ↗Read more →Caloric Intake in Renal Patients: Repercussions on Mineral Metabolism
Caloric intake has been shown to modulate P balance in experimental models: high caloric intake promotes P retention, while caloric restriction decreases plasma P concentrations.
Original paper ↗Read more →Changes of Serum Bone Metabolism Indexes and Ultrasonic Bone Mineral Density in Patients with Diabetic Nephropathy at Different Stages and their effects on Diabetic Renal Microvascular Complications
Differences in serum bone metabolism indexes and ultrasound BMD levels were compared.
Original paper ↗Read more →Clinical Anterior Segment and Ocular Surface Findings Across Renal Replacement Modalities: Associations with CKD-Related Factors, Mineral Metabolism and Activin A
While retinal manifestations of CKD have been increasingly investigated, data regarding clinical anterior segment modifications and their relationship with systemic biochemical parameters remain limited.
Original paper ↗Read more →Effect of kidney donation on bone mineral metabolism
Kidney donation results in reductions in kidney function and lasting perturbations in phosphate homeostasis, which may lead to adverse cardiovascular sequelae.
Original paper ↗Read more →Epidemiology of 40 blood biomarkers of one-carbon metabolism, vitamin status, inflammation, and renal and endothelial function among cancer-free older adults
Imbalances of blood biomarkers are associated with disease, and biomarkers may also vary non-pathologically across population groups.
Original paper ↗Read more →Evaluation of Bone Mineral Metabolism in Pre-Dialysis Chronic Kidney Disease: Quantitative Computed Tomography vs. Dual-Energy Absorptiometry and Correlation with Bone Turnover Markers
Background and Objectives: Bone and mineral disease (BMD) is a prevalent complication of advanced chronic kidney disease (CKD).
Original paper ↗Read more →Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder
In this study, we investigated the expression of miRNAs in CKD-MBD.
Original paper ↗Read more →Life-supporting functional kidney replacement by integration of embryonic metanephros-bladder composite tissue transplants
Novel transplantable organs need to be developed to address the global organ shortage.
Original paper ↗Read more →Markers of Bone Metabolism Are Affected by Renal Function and Growth Hormone Therapy in Children with Chronic Kidney Disease
41 children receiving recombinant growth hormone therapy were compared to an untreated matched control group.
Original paper ↗Read more →Modeling cellular responses to serum and vitamin D in microgravity using a human kidney microphysiological system
We used this unique environment to evaluate the effects of microgravity on kidney proximal tubule epithelial cell (PTEC) response to serum exposure and vitamin D biotransformation capacity.
Original paper ↗Read more →Perirenal fat differs in patients with chronic kidney disease receiving different vitamin D-based treatments: a preliminary study
Although it has not been widely evaluated, the fat surrounding the kidneys, or the perirenal adipose tissue (PAT), could also share similarities with the epicardial in terms of its potential contribution to the CVD risk observed in these patients.
Original paper ↗Read more →Renal Endocytic Regulation of Vitamin D Metabolism during Maturation and Aging in Laying Hens
Therefore, the present study aimed to examine the expression and localization of Meg and CUB in the kidneys of immature chicks and mature and aged laying hens to prevent eggshell quality deterioration.
Original paper ↗Read more →Retinal Structural and Microvascular Findings on OCT and OCTA in Hemodialysis and Kidney Transplant Recipients and Their Association with Mineral Metabolism Parameters
Background: Chronic kidney disease (CKD) is associated with systemic microvascular dysfunction, yet the relationship between retinal changes and mineral metabolism disturbances across CKD treatment modalities remains incompletely characterized.
Original paper ↗Read more →Short and long-term effects of kidney donation on mineral and bone metabolism
The effects of these changes should be investigated in further studies.
Original paper ↗Read more →The Role of Vitamin D Metabolism Genes and Their Genomic Background in Shaping Cyclosporine A Dosage Parameters after Kidney Transplantation
Kidney transplantation is followed by immunosuppressive therapy involving calcineurin inhibitors (CNIs) such as cyclosporin A.
Original paper ↗Read more →Vitamin D, Cellular Senescence and Chronic Kidney Diseases: What Is Missing in the Equation?
As life expectancy increases in many countries, the prevalence of age-related diseases also rises.
Original paper ↗Read more →Vitamin D metabolism in critically ill patients with acute kidney injury: a prospective observational study
We aimed to compare the longitudinal profiles of serum 25(OH)D and 1,25(OH)2D concentrations in critically ill patients with and without moderate to severe AKI and explore the impact of renal recovery and parathyroid hormone (PTH).
Original paper ↗Read more →